Tags : Chronic Kidney Disease


AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI

Shots: AstraZeneca has selected a novel CKD target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter its portfolio In 2019, companies collaborated to discover new drugs for CKD and IPF The collaboration leverages AstraZeneca’s scientific expertise and rich datasets with BenevolentAI’s target identification platform to […]Read More

Clinical Trials

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for

Shots: The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results […]Read More


Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More